Saiz Augustine M, Gingrich Alicia A, Canter Robert J, Kirane Amanda R, Monjazeb Arta M, Randall R Lor, Thorpe Steven W
Sarcoma Services, MSK Section, Department of Orthopaedic Surgery, UC Davis Medical Center, Sacramento, CA 95817, USA.
Division of Surgical Oncology, Department of Surgery, UC Davis Medical Center, Sacramento, CA 95817, USA.
Sarcoma. 2019 Apr 24;2019:5413527. doi: 10.1155/2019/5413527. eCollection 2019.
Radiation therapy (RT) is advocated in the multimodal treatment of high-grade soft tissue sarcoma (STS), but its role may be less clear in chemotherapy-sensitive STS such as extraskeletal Ewing sarcoma (EES). The purpose of this study was to determine the role of RT on overall survival (OS) in localized EES adult patients treated with chemotherapy and surgery. Adult patients diagnosed with EES and reported to the National Cancer Database from 2004 to 2014 were evaluated. All patients were treated with surgical resection. Patient demographics, tumor characteristics, treatments received, resection margins, and survival were examined for the 232 patients identified. Using multivariate analysis and Cox proportional hazard analysis, predictors of OS were determined. In the overall cohort, 40 percent of patients received RT and 78 percent received chemotherapy, with 31 percent receiving both. The addition of RT to the patients receiving surgery + chemotherapy did not improve OS ( < 0.05). Twenty-four percent of patients who achieved R0 resection after surgery still received RT without any improvement in OS. Patients treated at community cancer centers were more likely to receive additional RT compared with Comprehensive Cancer Centers ( < 0.05). In adult EES patients with localized disease treated with chemotherapy and surgery, the addition of RT does not improve overall survival.
放射治疗(RT)在高级别软组织肉瘤(STS)的多模式治疗中得到提倡,但在化疗敏感的STS(如骨外尤文肉瘤(EES))中其作用可能不太明确。本研究的目的是确定放疗对接受化疗和手术的局限性EES成年患者总生存期(OS)的作用。对2004年至2014年诊断为EES并报告至国家癌症数据库的成年患者进行评估。所有患者均接受手术切除。对确定的232例患者的人口统计学特征、肿瘤特征、接受的治疗、手术切缘和生存情况进行了检查。使用多变量分析和Cox比例风险分析确定总生存期的预测因素。在整个队列中,40%的患者接受了放疗,78%的患者接受了化疗,31%的患者两者都接受。在接受手术+化疗的患者中加用放疗并未改善总生存期(P<0.05)。24%术后实现R0切除的患者仍接受放疗,但总生存期没有改善。与综合癌症中心相比,在社区癌症中心接受治疗的患者更有可能接受额外的放疗(P<0.05)。在接受化疗和手术治疗的局限性疾病成年EES患者中,加用放疗并不能改善总生存期。